Yuan‑zhi‑san inhibits tau protein aggregation in an Aβ1‑40‑induced Alzheimer's disease rat model via the ubiquitin‑proteasome system
- PMID: 33604685
- PMCID: PMC7893680
- DOI: 10.3892/mmr.2021.11918
Yuan‑zhi‑san inhibits tau protein aggregation in an Aβ1‑40‑induced Alzheimer's disease rat model via the ubiquitin‑proteasome system
Abstract
Yuan‑zhi‑san (YZS) is a classic type of Traditional Chinese Medicine, which has been reported to aid in the treatment of Alzheimer's disease (AD). The present study aimed to investigate the effects of YZS on tau protein aggregation, a hallmark of AD pathology, and its possible mechanisms. The results demonstrated that YZS improved learning and memory abilities, and decreased the severity of AD pathology in β‑amyloid (Aβ1‑40)‑induced AD rats. Moreover, YZS administration inhibited the hyperphosphorylation of tau protein at Ser199 and Thr231 sites. Several vital enzymes in the ubiquitin‑proteasome system (UPS), including ubiquitin‑activating enzyme E1a/b, ubiquitin‑conjugating enzyme E2a, carboxyl terminus of Hsc70‑interacting protein, ubiquitin C‑236 terminal hydrolase L1 and 26S proteasome, were all significantly downregulated in AD rats, which indicated an impaired enzymatic cascade in the UPS. In addition, it was identified that YZS treatment partly increased the expression levels of these enzymes in the brains of AD rats. In conclusion, the present results suggested that YZS could effectively suppress the hyperphosphorylation of tau proteins, which may be partially associated with its beneficial role in restoring functionality of the UPS.
Keywords: Alzheimer's disease; Yuan‑zhi‑san; tau protein; ubiquitin‑proteasome system.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures





Similar articles
-
Purpurin modulates Tau-derived VQIVYK fibrillization and ameliorates Alzheimer's disease-like symptoms in animal model.Cell Mol Life Sci. 2020 Jul;77(14):2795-2813. doi: 10.1007/s00018-019-03312-0. Epub 2019 Sep 27. Cell Mol Life Sci. 2020. PMID: 31562564 Free PMC article.
-
Fuzhisan Ameliorates the Memory Deficits in Aged SAMP8 Mice via Decreasing Aβ Production and Tau Hyperphosphorylation of the Hippocampus.Neurochem Res. 2016 Nov;41(11):3074-3082. doi: 10.1007/s11064-016-2028-4. Epub 2016 Aug 12. Neurochem Res. 2016. PMID: 27518086
-
Notopterygium incisum extract (NRE) rescues cognitive deficits in APP/PS1 Alzhneimer's disease mice by attenuating amyloid-beta, tau, and neuroinflammation pathology.J Ethnopharmacol. 2020 Mar 1;249:112433. doi: 10.1016/j.jep.2019.112433. Epub 2019 Nov 27. J Ethnopharmacol. 2020. PMID: 31783135
-
Disrupted ubiquitin proteasome system underlying tau accumulation in Alzheimer's disease.Neurobiol Aging. 2021 Mar;99:79-85. doi: 10.1016/j.neurobiolaging.2020.11.015. Epub 2020 Dec 8. Neurobiol Aging. 2021. PMID: 33422896 Review.
-
Exploring the Role of Aggregated Proteomes in the Pathogenesis of Alzheimer's Disease.Curr Protein Pept Sci. 2020;21(12):1164-1173. doi: 10.2174/1389203721666200921152246. Curr Protein Pept Sci. 2020. PMID: 32957903 Review.
Cited by
-
Network pharmacology implicates traditional Chinese medicine in regulating systemic homeostasis to benefit Alzheimer's disease.Tzu Chi Med J. 2023 Feb 13;35(2):120-130. doi: 10.4103/tcmj.tcmj_125_22. eCollection 2023 Apr-Jun. Tzu Chi Med J. 2023. PMID: 37261294 Free PMC article. Review.
-
Active Compounds and Targets of Yuanzhi Powder in Treating Alzheimer's Disease and Its Relationship with Immune Infiltration Based on HPLC Fingerprint and Network Pharmacology.Evid Based Complement Alternat Med. 2022 Jul 15;2022:3389180. doi: 10.1155/2022/3389180. eCollection 2022. Evid Based Complement Alternat Med. 2022. PMID: 35873623 Free PMC article.
-
Ginsenoside Rb1 Lessens Gastric Precancerous Lesions by Interfering With β-Catenin/TCF4 Interaction.Front Pharmacol. 2021 Sep 14;12:682713. doi: 10.3389/fphar.2021.682713. eCollection 2021. Front Pharmacol. 2021. PMID: 34594214 Free PMC article.
-
Yuan-Zhi decoction in the treatment of Alzheimer's disease: An integrated approach based on chemical profiling, network pharmacology, molecular docking and experimental evaluation.Front Pharmacol. 2022 Aug 24;13:893244. doi: 10.3389/fphar.2022.893244. eCollection 2022. Front Pharmacol. 2022. PMID: 36091836 Free PMC article.
References
-
- Zhang HN, Wang MR, Chen XL, Xu YJ, Li J, Wang HL, Du J. Research on the content construction of dementia management in community based on Delphi method. Chin Gen Pract. 2020;23:2072–2079.
-
- Patterson C. World Alzheimer report 2018-The state of the art of dementia research: New frontiers. Alzheimer's Disease International (ADI) 2018:1–48.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous